Patents by Inventor Tianci Luo
Tianci Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9238057Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.Type: GrantFiled: December 17, 2012Date of Patent: January 19, 2016Assignee: Novartis AGInventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
-
Patent number: 9228003Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: GrantFiled: May 4, 2012Date of Patent: January 5, 2016Assignee: Wellstat Immuno Therapeutics, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Publication number: 20140328821Abstract: The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment.Type: ApplicationFiled: October 26, 2012Publication date: November 6, 2014Applicant: Wellstat Ophthalmics CorporationInventor: Tianci Luo
-
Publication number: 20140249072Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: ApplicationFiled: May 4, 2012Publication date: September 4, 2014Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Publication number: 20130165503Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.Type: ApplicationFiled: December 17, 2012Publication date: June 27, 2013Applicant: NOVARTIS AGInventors: Romulus Kimbro BRAZZELL, Peter Anthony CAMPOCHIARO, Katharine Hilary DIXON, Michael KALEKO, Tianci LUO
-
Patent number: 8338384Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.Type: GrantFiled: May 23, 2010Date of Patent: December 25, 2012Assignee: Novartis AGInventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
-
Patent number: 8236558Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.Type: GrantFiled: August 30, 2010Date of Patent: August 7, 2012Assignee: Novartis AGInventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
-
Patent number: 8183356Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.Type: GrantFiled: February 5, 2007Date of Patent: May 22, 2012Assignee: Novartis AGInventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Lynn Douglas
-
Publication number: 20110171733Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.Type: ApplicationFiled: August 30, 2010Publication date: July 14, 2011Inventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Publication number: 20100286253Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.Type: ApplicationFiled: May 23, 2010Publication date: November 11, 2010Applicant: NOVARTIS AGInventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
-
Patent number: 7785877Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: August 31, 2010Assignee: Novartis AGInventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
-
Publication number: 20100120665Abstract: The invention provides, in part, methods, nucleic acids, vectors, proteins and binding molecules that can be used to modulate a pathway such as a complement pathway. These methods and compositions can be utilized, inter alia, for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: ApplicationFiled: February 29, 2008Publication date: May 13, 2010Applicant: ADVANCED VISION THERAPIES, INC.Inventors: Michael Kaleko, Tianci Luo
-
Patent number: 7700342Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.Type: GrantFiled: June 30, 2006Date of Patent: April 20, 2010Assignee: Novartis AGInventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Lynn Douglas
-
Patent number: 7662621Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: December 14, 2006Date of Patent: February 16, 2010Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Publication number: 20090093040Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: ApplicationFiled: March 8, 2005Publication date: April 9, 2009Inventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Publication number: 20080268522Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.Type: ApplicationFiled: June 30, 2006Publication date: October 30, 2008Applicant: Novartis AGInventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Lynn Douglas
-
Patent number: 7442551Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.Type: GrantFiled: June 30, 2006Date of Patent: October 28, 2008Assignee: Novartis AGInventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Lynn Douglas
-
Publication number: 20080021207Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.Type: ApplicationFiled: February 5, 2007Publication date: January 24, 2008Applicant: Novartis AGInventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Douglas
-
Publication number: 20070207546Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: ApplicationFiled: December 14, 2006Publication date: September 6, 2007Applicant: Novartis AGInventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
-
Patent number: 7202079Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 10, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko